Abiraterone Acetate Soars with Pre-Chemotherapy Indication


abiraterone acetateKnown as the prostate cancer powerhouse treatment Zytiga, Abiraterone Acetate has recently become a sales powerhouse for Medivation. The reason for the hype centers on a new indication for this potent anti-cancer drug, specifically as an efficacious pre-chemo treatment. Initial FDA approval for Abiraterone was for post-chemotherapy only. As a post-chemo treatment Zytiga was by no means losing money, with roughly one billion dollars in sales annually. The latest indication for Abiraterone as pre-chemotherapy treatment has increased profits and future estimates by 700 million dollars a year. Medivation currently holds the top spot for post-chemo therapy, and the forecast for them becoming a market share leader in pre-chemo therapy looks unusually bright.

prostate cancerThe most recent indication for Abiraterone Acetate is based on positive clinical trial results involving 1,088 men stricken with metastatic castration-resistant prostate cancer, or mCRPC. Patients enrolled in this study experienced disease progression while on androgen deprivation and had not yet been administered chemotherapy. Abiraterone was administered to the trial participants alongside Prednisone, and this combination proved to be very encouraging. The average survival was 35.3 months’ time for the men who received the Abiraterone and Prednisone duo, as compared to 30.1 months mean overall survival for the males who were given a placebo and Prednisone. Additionally, fewer men in the study saw a progression of mCRPC disease when they were given the Abiraterone and Prednisone combination. Roughly 28 percent of participants dosed with Abiraterone and Prednisone showed disease progression via imaging studies. This figure is astoundingly better than the 46 percent of men who suffered from disease progression in the placebo plus Prednisone study group.

As an oral medication intended to be used in combination with Prednisone for the treatment of advanced prostate cancer, Abiraterone Acetate is used once daily. Side effects can include weakness or joint swelling and pain, anemia, bruising and diarrhea. Abiraterone is an effective inhibitor of androgen biosynthesis that has become essential for treating the second most common cause of cancer in men. The American Cancer Society estimates there will be 220,800 new cases of prostate cancer and 27, 540 deaths from this virulent disease in 2015. One in every seven men are expected to be diagnosed with prostate cancer in his lifetime. While the majority of cases occur in men ages 65 and older there are cases of men being diagnosed at earlier ages. These grim statistics are not without hope however, as over 2.7 adult American men have been diagnosed with prostate cancer and are today considered survivors. Many patients complete treatment with Abiraterone and go on to receive subsequent chemotherapy, most commonly with Docetaxel. Further, or post-chemotherapy treatment usually includes additional Abiraterone and Prednisone therapy.

The use of Abiraterone has been touted in several studies, showing that about 70 percent of patients who were treated with this drug experienced a 50 percent decline in PSA levels overall, as compared to 29 percent of patients who did not receive Abiraterone. This mighty medication is also generally well tolerated, with grade four adverse events being rare. Exciting findings are expected at the 2015 Genitourinary Cancers Symposium regarding Abiraterone Acetate. LGM Pharma can assist clients as a supplier/distributor of the API Abiraterone Acetate, CAS # 154229-18-2, as well as Prednisone, CAS # 53-03-2 and Docetaxel, CAS # 114977-28-5 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: